Patho.Ai On Prem LLM Accelerator N: Unleash Protein Drug Discovery Power

Uncover Faster Results

The Patho.Ai On Prem LLM Accelerator N leverages a Large Language Model (LLM) and a Xilinx U280 FPGA PCI board to significantly accelerate protein drug discovery. The multi-agent architecture optimizes the process, leading to faster breakthroughs in medical research.

Xilinx U280 FPGA: Powering Patho.Ai On Prem LLM Accelerator N

• High Performance: Delivering up to 409 TOPS (Tera Operations Per Second), the Xilinx U280 turbocharges your LLM inference, accelerating protein analysis for faster drug discovery.
• Scalability: The U280 adapts to your needs. Its scalable architecture allows you to tailor the Patho.Ai On Prem LLM Accelerator X to your specific protein research requirements.
• Programmability: Unmatched customization. The programmable nature of the U280 FPGA empowers you to design the ideal protein analysis pipeline for your unique research goals.
• Connectivity: PCI Express® Gen3 x16 or Gen4 x8 ensures seamless data transfer between the FPGA and the host system for efficient protein analysis.
• Memory Powerhouse: Equipped with 64GB of high-bandwidth HBM2 memory and two 256GB DDR4 RDIMMs, the U280 provides ample resources to handle complex protein data analysis.

Multi-Agent Advantage

The Patho.Ai On Prem LLM Accelerator N incorporates a multi-agent architecture, distributing tasks across multiple processing units. This parallel processing approach significantly reduces computation time, leading to faster protein drug discovery results.

Conclusion

The Patho.Ai On Prem LLM Accelerator N delivers a powerful combination for accelerating protein drug discovery. With the Xilinx U280 FPGA at its core, researchers can unlock faster breakthroughs in the fight against disease.